Search Results for

EAA171

Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Continue Reading »

---

S1803

Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

Continue Reading »

---

Search Again

• All Trial Categories Anal  (2) Bladder/Urinary Tract Cancer  (7)    Metastatic  (3)    Neoadjuvant  (4) Brain  (7)    Glioblastoma Multiforme (GBM)  (3)    Other Brain Tumors  (3) Breast  (17)    1st Line Metastatic Breast, Metastasis at Presentation or Progression of earlier Disease  (4)    2nd Line Metastatic Breast, Progressive Disease Following 1st Line Therapy  (1)    Breast Cancer Adjuvant  (3)    DCIS/LCIS  (1) Cancer Control/Symptom Management  (19) Colorectal Cancer  (8)    Metastatic  (3)    Rectal Neoadjuvant  (1) Esophageal Cancer  (2) Gall Bladder/ Biliary Tract Cancer  (2) Gastric Cancer  (1)    Metastaic Gastric Cancer  (1) Head/Neck Cancer  (5)    Resectable Oral Cavity Cancer  (1)       Primary Chemoradiation Regimens  (1) Leukemia  (6)    Acute Myeloid Leukemia (AML)  (1)    B-Cell Chromic Lymphocytic Leukemia (CLL) / Small Ly  (3) Liver/Hepatocellular Carcinoma  (1) Lung Cancer  (26)    Non-Small Cell Lung Cancer  (18)       1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence  (5)       2nd Line Metastatic, Stage 4 Patients with Progressive Disease  (3)       Adjuvant Treatment for Resected NSCLC  (3)    Small Cell Lung Cancer  (8)       Extensive Stage SCLC  (5) Lymphoma  (5)    Non-Hodgkin’s Lymphoma  (2)       Follicular Lymphoma  (1)          Relapsed/Refractory  (1) MATCH Trial  (1) MDS  (3) Melanoma  (5)    Metastatic  (2) Merkel Cell Carcinoma  (1) Multiple Myeloma  (2) Pancreatic  (4)    Metastatic Disease  (2) Prostate  (10) Renal Cell/Kidney Cancer  (4)    Locally Advanced/Metastatic  (4) Sarcoma  (2) Small Bowel  (1)